《新股消息》天任集团(01429.HK)公开发售超购近26倍 一手中签率12.5%
天任集团(01429.HK)公布招股结果,以0.35元定价,为下限定价(招股价介乎0.35元至0.44元),香港公开发售部分超额认购25.76倍,经重新分配後,公开发售股数增至占整体20%;一手8,000股,中签率为12.5%。该股将於明日(9月29日)上市。同人融资为独家保荐人。
公司预计所得款项净额将约为8,320万元,当中约60.8%用於支付若干前期成本及开支、拟投标的未来项目而用於系统模板的铝模板的购置成本;21.6%用於增加金属通架设备及相关零件库存;9%用作进一步加强人力资源;以及余下8.6%用作集团一般营运资金用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.